1. Immuno-efficacy of DNA vaccines encoding PLP1 and ROP18 against experimental Toxoplasma gondii infection in mice.
- Author
-
Chen Y, Yu M, Hemandez JA, Li J, Yuan ZG, and Yan H
- Subjects
- Animals, Antibodies, Protozoan biosynthesis, Brain parasitology, Cytokines analysis, Female, Fluorescent Antibody Technique, Indirect, Immunoglobulin G analysis, Immunoglobulin G biosynthesis, Injections, Intramuscular, Mice, Myelin Proteolipid Protein genetics, Plasmids, Protein Serine-Threonine Kinases genetics, Protozoan Proteins, Specific Pathogen-Free Organisms, Spleen cytology, Spleen immunology, Survival Analysis, Toxoplasmosis, Animal mortality, Myelin Proteolipid Protein immunology, Protein Serine-Threonine Kinases immunology, Protozoan Vaccines administration & dosage, Protozoan Vaccines immunology, Protozoan Vaccines standards, Toxoplasma immunology, Toxoplasmosis, Animal prevention & control, Vaccines, DNA administration & dosage, Vaccines, DNA immunology, Vaccines, DNA standards
- Abstract
We constructed a new plasmid pIRESneo/ROP18/PLP1 that was injected intramuscularly into Kunming mice to evaluate its immune efficacy. The immunized mice exhibited significantly increased serum IgG2a levels, lymphocyte counts and Th1-type cytokine (IL-2, IL-12 and IFN-γ) levels. Moreover, the immunized mice exhibited longer survival times (44.7 ± 2.1 days for ROP18/PLP1 and 47.2 ± 2.9 days for ROP18/PLP1 + IL-18) and lower brain cyst burden (68.9% for ROP18/PLP1 and 72.4% for ROP18/PLP1 + IL-18) than control mice after T. gondii challenge. Our results demonstrate that the multiple-gene DNA vaccine including both ROP18 and PLP1 elicits greater protection against T. gondii challenge and stronger immunogenicity than single-gene vaccines., (Copyright © 2018 Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF